UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036589
Receipt number R000041681
Scientific Title Retrospective cohort analysis of the factor related to the effect of tolvaptan on the medium-and-long term prognosis in patients with hepatic edema
Date of disclosure of the study information 2019/05/01
Last modified on 2020/11/15 18:04:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Retrospective cohort analysis of the factor related to the effect of tolvaptan on the medium-and-long term prognosis in patients with hepatic edema

Acronym

clinical trial of tolvaptan for hepatic edema

Scientific Title

Retrospective cohort analysis of the factor related to the effect of tolvaptan on the medium-and-long term prognosis in patients with hepatic edema

Scientific Title:Acronym

clinical trial of tolvaptan for hepatic edema

Region

Japan


Condition

Condition

hepatic edema

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We will evaluate influence that tolvaptan for hepatic edema will give the prognosis of the cirrhotic patient, and intend that I clarify optimum time of the introduction of tolvaptan by clarifying the patient baseline factor which influenced the prognosis of the cirrhotic patient under tolvaptan.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the survival days of the cirrhotic patientunder tolvaptan

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <

Age-upper limit

90 years-old >

Gender

Male and Female

Key inclusion criteria

1)Age 20 years old or older
2)The patient that an own strength walk is possible
3)The patient who can list in an interview vote by oneself
4)the patient that agree the participation to this
5)The patient who meets the following clinical inspection standards
a) A hemoglobin level: >= 8.0 g/dl
b) A neutrophilic number: >= 1,000/mm3
c) The number of the platelets: >= 30,000/mm3
e) ALT and AST level: 6 times of the <= facilities standard

Key exclusion criteria

1) The patient who has an applicable heart trouble as follows
a) Congestive heart failures more than NYHA class 3
b) The high blood pressure that it is poor in control
2) Dangerously ill patient (except HBV, the HCV) who and has an infectious disease of the activity
3) Patient with a history of the HIV infection
4) Patient during hemodialysis
6) Patient of hepatic encephalopathy having difficulty in appropriate hydration
7) The patient who was treated whom patient 8) who produced the gastrointestinal tract bleeding that a blood transfusion and measures need within four weeks before this study start corresponds below to
a) Whole body chemotherapy within four weeks before this study start
b) The patient who has difficulty in 9 operation) drug remedy under the general anesthesia within four weeks before this study start
10) When may spoil the security of the patient in 13 patient) others affecting the evaluation of this study entry and result, this study enforcement or when the observance of this study enforcement plan is judged with difficulty by 12 patient) drug abuse that may wake up an allergic reaction for possibility of during a pregnant woman, the nursing and the pregnancy or this patient
11) study drug with the intention

Target sample size

400


Research contact person

Name of lead principal investigator

1st name IWASHITA
Middle name
Last name AI

Organization

NIPPON MEDICAL SCHOOL HOSPITAL

Division name

gastroenterology

Zip code

113-0022

Address

1-1-5, Sendagi, Bunkyo-ku, Tokyo

TEL

03-3824-2332

Email

a0520i@nms.ac.jp


Public contact

Name of contact person

1st name IWASHITA
Middle name
Last name AI

Organization

NIPPON MEDICAL SCHOOL HOSPITAL

Division name

gastroenterology

Zip code

113-0022

Address

1-1-5, Sendagi, Bunkyo-ku, Tokyo

TEL

03-3824-2332

Homepage URL


Email

a0520i@nms.ac.jp


Sponsor or person

Institute

NIPPON MEDICAL SCHOOL HOSPITAL

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

NIPPON MEDICAL SCHOOL HOSPITAL

Address

1-1-5, Sendagi, Bunkyo-ku, Tokyo

Tel

03-3824-2332

Email

a0520i@nms.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 05 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2019 Year 04 Month 01 Day

Date of IRB

2019 Year 06 Month 01 Day

Anticipated trial start date

2019 Year 06 Month 01 Day

Last follow-up date

2019 Year 06 Month 30 Day

Date of closure to data entry

2019 Year 06 Month 30 Day

Date trial data considered complete

2019 Year 07 Month 30 Day

Date analysis concluded

2019 Year 09 Month 30 Day


Other

Other related information

none


Management information

Registered date

2019 Year 04 Month 24 Day

Last modified on

2020 Year 11 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041681


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name